BioNotebook: Seragon, Arcturus, Seattle Genetics, Cytos, CIRM

Seragon announces Series A funding amount; Arcturus raises $5m Series A; Seattle Genetics enters clinic with new ADC; Cytos earns Phase IIb cash; and CIRM president steps down.

More from Anticancer

More from Therapy Areas